01
Overview
Oticara is a clinical-stage pharmaceutical company developing innovative in-office treatments for ENT physicians to address challenging ear and sinus conditions. Their lead programs target patients with persistent symptoms after endoscopic sinus surgery and those suffering from acute or fungal-driven outer ear infections. Early clinical results have shown statistically significant symptom reduction in post-surgical chronic rhinosinusitis and rapid resolution of mixed bacterial/fungal otitis externa, with further studies planned to validate these findings.
- Therapeutic areas
- ImmunologyPulmonologyInfectious Diseases
- Modalities
- Small moleculesCombination anti-infective therapies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Oticara.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oticara.